Telaprevir Versus Boceprevir in Chronic Hepatitis C: A Meta-Analysis of Data From Phase II and III Trials

Clinical Therapeutics

Volumn 35, Issue 2, 2013, Pages 190-197

  Sitole, Mugdha ^a   Silva, Matthew ^a   Spooner, Linda ^a   Comee, Morgan K ^a   Malloy, Michael ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Boceprevir; Chronic hepatitis C; Hepatitis C genotype 1; Protease inhibitors; Telaprevir

Indexed keywords

BOCEPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

ANEMIA; CHILL; CLINICAL PROTOCOL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGEUSIA; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HOSPITALIZATION; HUMAN; LOADING DRUG DOSE; META ANALYSIS; MORTALITY; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENT DISEASE; RELAPSE; REVIEW; RISK REDUCTION; SUSTAINED VIRAL RESPONSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84873580144     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.12.017     Document Type: Review

References (24)

1. McHutchison J.G., Manns M.P., Muir A.J., et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010, 362:1292-1303.
2. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
3. McHutchison J.G., Everson G.T., Gordon S.C., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838.
4. Hezode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850.
5. Muir A.J., Bornstein J.D., Killenberg P.G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350:2265-2271.
6. Glue P., Fang J.W., Rouzier-Panis R., et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000, 68:556-567. Hepatitis C Intervention Therapy Group.
7. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
8. Chung R.T., Andersen J., Volberding P., et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451-459.
9. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351:438-450.
10. Kwo P.Y., Lawitz E.J., McCone J., et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
11. FDA approves Victrelis for Hepatitis C US Food and Drug Administration, Accessed September 5, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm255390.htm.
12. Approval of Incivek (telaprevir), a direct acting antiviral drug (DAA) to treat hepatitis C (HCV) US Food and Drug Administration, Accessed April 27, 2012. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm256328.htm.
13. Victrelis (boceprevir) [prescribing information] 2012, Merck, Whitehouse Station, NJ.
14. Incivek (telaprevir) [prescribing information] 2012, Vertex Pharmaceuticals Inc, Cambridge, Mass.
15. Sherman K.E., Flamm S.L., Afdhal N.H., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011, 365:1014-1024.
16. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
17. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
18. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
19. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
20. Ioannidis J.P. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract 2008, 14:951-957.
21. Sutton A.J., Abrams K.R., Sheldon T.A., Song F. Publication bias. Methods for Meta-Analysis in Medical Research 2000, JD, John Wiley & Sons, Chichester, UK. 1 ed.
22. Higgins J.P.T., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
23. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
24. Kumada H., Toyota J., Okanoue T., et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012, 56:78-84.